Clinical Usefulness of Hydromorphone-OROS in Improving Sleep Disturbances in Korean Cancer Patients: A Multicenter, Prospective, Open-Label Study / Journal of the Korean Cancer Association, 대한암학회지
Cancer Research and Treatment
;
: 331-338, 2014.
Article
in English
| WPRIM
| ID: wpr-8784
ABSTRACT
PURPOSE:
To evaluate the efficacy of hydromorphone-OROS (HM-OROS) in reducing sleep disturbance and relieving cancer pain. MATERIALS ANDMETHODS:
One hundred twenty cancer patients with pain (numeric rating scale [NRS] > or = 4) and sleep disturbance (NRS > or = 4) were evaluated. The initial HM-OROS dosing was based on previous opioid dose (HM-OROSoral morphine=15). Dose adjustment of the study drug was permitted at the investigator\'s discretion. Pain intensity, number of breakthrough pain episodes, and quality of sleep were evaluated.RESULTS:
A total of 120 patients received at least one dose of HM-OROS; 74 of them completed the final assessment. Compared to the previous opioids, HM-OROS reduced the average pain NRS from 5.3 to 4.1 (p < 0.01), worst pain NRS from 6.7 to 5.4 (p < 0.01), sleep disturbance NRS from 5.9 to 4.1 (p < 0.01), incidence of breakthrough pain at night from 2.63 to 1.53 times (p < 0.001), and immediate-release opioids use for the management of breakthrough pain from 0.83 to 0.39 times per night (p = 0.001). Of the 74 patients who completed the treatment, 83.7% indicated that they preferred HM-OROS to the previous medication. The adverse events (AEs) were somnolence, asthenia, constipation, dizziness, and nausea.CONCLUSION:
HM-OROS was efficacious in reducing cancer pain and associated sleep disturbances. The AEs were manageable.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Asthenia
/
Incidence
/
Prospective Studies
/
Constipation
/
Dizziness
/
Breakthrough Pain
/
Analgesics, Opioid
/
Nausea
Type of study:
Controlled clinical trial
/
Incidence study
/
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Cancer Research and Treatment
Year:
2014
Type:
Article
Similar
MEDLINE
...
LILACS
LIS